# Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.

> **NCT00563459** · PHASE3 · TERMINATED · sponsor: **SK Life Science, Inc.** · enrollment: 89 (actual)

## Conditions studied

- Epilepsy
- Seizures

## Interventions

- **DRUG:** carisbamate
- **DRUG:** topiramate
- **DRUG:** levetiracetam

## Key facts

- **NCT ID:** NCT00563459
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 89 (ACTUAL)
- **Why stopped:** Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this indication were terminated.
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563459, "Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00563459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*